Fusataka Koide joined Southern Research’s Infectious Disease program in Frederick, Maryland, in 2007, where he is currently senior project leader for the In Vivo Emerging Pathogen Program. In this role he serves as project leader, testing various vaccines and anti-viral drugs in non-human primate (NHP) and small animal models. Koide is an expert in the infectious disease in vivo models, and his research focuses include assessment of vaccine immunogenicity and efficacy in NHP. He has more than 14 years of experience in the development of vaccine animal models. Koide also serves as liaison to various Japanese pharmaceutical companies as Japan business development manager.*
Throughout his tenure at SR, he has directed multiple PHS-funded projects under ABSL 2/3 environment; led studies including efficacy evaluation of anti-orthopoxvirus immunotherapeutic, immunogenicity and efficacy of combination VEE Replicon Particles (VRP); and directed the immunogenicity and protective efficacy evaluation of live attenuated H7N7 and H7N9 vaccines. Koide is currently directing assay development and GLP-enabling assay validation for flavivirus.
In May of 2000, Koide joined Dr. Philip Livingston’s laboratory in the Department of Tumor Vaccinology at Memorial Sloan-Kettering Cancer Center to work on murine immunogenicity and toxicity studies of a newly developed cancer vaccines. He was also involved in more than ten FDA Phase I and Phase II clinical trial projects. Koide was also a project lead in the development of an animal model for a gene-gun and electroporation DNA vaccine delivery project. At Nabi Biopharmaceuticals, where he was involved in research and development of a pentavalent vaccine against Methicillin-resistant Staphylococcus aureus (MRSA), he acquired knowledge and expertise in mouse and rabbit efficacy models for infectious disease.
Additionally, Koide has led the dengue virus (DENV) in vivo model development in NHP, and his work was published during 2010 American Society for Microbiology Annual Meeting. He is currently managing and executing multiple dengue vaccine projects as PI, including immunogenicity and efficacy assessment of tetravalent dengue vaccine candidates in cynomolgus monkeys (GLP study). His most recent research interests focus on the animal model development for Zika virus infection in NHP and small animal models.
Koide obtained his master’s in immunology and microbiology at the New York Medical College.
* SR is providing research support solutions to a growing Japan market through official distributor CosmoBio.